Elranatamab: Uses, Dosing, and Side Effects for Myeloma

Elranatamab is a bispecific antibody approved for adults with relapsed or refractory multiple myeloma who have already been through at least four prior lines of treatment, including the three major drug classes (a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody). It received approval from both the FDA and the EMA in 2023 based on the MagnetisMM-3 trial, which showed that about six in ten heavily pretreated patients responded to treatment.¹ The drug works differently from standard chemotherapy, and its dosing, side-effect profile, and monitoring requirements reflect that difference in meaningful ways.

How Elranatamab Works

Elranatamab is designed to physically bridge two types of cells. One arm of the antibody latches onto BCMA, a protein found on the surface of myeloma cells. The other arm grabs CD3, a molecule on T cells (immune cells that can kill cancer). By connecting a T cell directly to a myeloma cell, elranatamab forces an immune attack that the cancer would otherwise evade. This activation does not depend on how the T cell’s own receptor is normally programmed, so it works even when the immune system has been battered by prior treatments.² Once the T cell is activated, it releases molecules like perforin and granzyme B that punch holes in the myeloma cell and destroy it.

Approved Use and Who It Is For

The current approval covers adults with triple-class exposed or refractory multiple myeloma, meaning patients whose disease has been treated with (or stopped responding to) all three of the major drug categories used in earlier lines of therapy. In practice, these patients have few standard options left, and their expected outcomes with conventional retreatment are poor. An updated comparison adjusting for differences between trial populations found that elranatamab offered significantly better progression-free survival and overall survival compared with physician’s choice of treatment in this setting.¹

How Well It Works

In the MagnetisMM-3 trial, which enrolled 123 patients who had not previously received BCMA-directed therapy, about 61% achieved a confirmed response after a median follow-up of roughly 15 months. More than a third of patients reached a complete response or better, and over half achieved at least a very good partial response. Responses came quickly, with a median time to first response of about 1.2 months. Among those who responded, the median duration of response had not yet been reached at the time of analysis, and about 72% of responders were still in response at 15 months. For patients who achieved a complete response, that figure was closer to 89%.³

Response rates were consistent across subgroups, including patients with high-risk cytogenetics and those with heavy bone marrow involvement at baseline.⁴ Quality-of-life data added further context: improvements in pain and disease symptoms showed up early, and over 40% of BCMA-naive patients reported feeling “a little better” or “much better” by the 15th day of the first treatment cycle.⁵

The Step-Up Dosing Schedule

Elranatamab is given as a subcutaneous injection, not an infusion. But you do not start at the full dose. The first few doses are “stepped up” to reduce the risk of a severe immune reaction. The standard approved priming regimen uses two step-up doses of 12 mg and 32 mg before reaching the full weekly dose of 76 mg. This schedule was chosen after modeling showed that starting at the full 44 mg (an earlier priming approach) would cause any-grade cytokine release syndrome in over 90% of patients. Splitting the ramp into 12 mg and 32 mg brought that rate down to about 58%, with severe cases dropping to roughly 14%.⁶

An alternative priming approach using even lower first doses (4 mg and 20 mg) was tested but actually resulted in slightly higher rates of CRS than the 12/32 mg regimen. The reasoning is that the very low first dose of 4 mg may not stimulate the immune system enough, so the second priming dose of 20 mg and the jump to 76 mg then catch the immune system off guard. The 12/32 mg schedule provided a more predictable CRS profile and was selected for routine use.⁶

Transitioning to Less Frequent Dosing

Patients who respond to elranatamab do not necessarily stay on weekly injections indefinitely. Data from the phase 1 MagnetisMM-1 trial showed that among responders who switched from weekly to every-two-week dosing after at least six months of treatment, 75% maintained or deepened their response.⁷ Pharmacologic modeling suggests this works because patients with a durable response have already eliminated most of the tumor burden, and less frequent dosing is sufficient to keep remaining cells in check. Simulations estimated that over 85% of patients who stayed in response after switching from weekly to every-two-week dosing would actually see greater tumor shrinkage than if they had continued on the weekly schedule, and a further step down to monthly dosing showed similar results.⁸

The practical benefit is substantial. Fewer clinic visits, fewer injections, and fewer days spent managing potential side effects all matter for patients who may be on treatment for years. Only about 17% of persistent responders who moved to every-two-week dosing showed disease progression within three years in the simulation data.⁸

Cytokine Release Syndrome

The most talked-about side effect of elranatamab is cytokine release syndrome. When T cells are suddenly activated against myeloma cells, they dump inflammatory signaling molecules (cytokines) into the bloodstream, causing fever, chills, low blood pressure, and sometimes difficulty breathing. CRS is most common during the step-up dosing phase and with early full doses. Higher drug concentrations in the blood during these early doses are associated with a greater chance of CRS, while premedication with corticosteroids and drugs that block a key cytokine called IL-6 reduce the risk.⁹

Most CRS events are mild (grade 1 or 2), meaning fever and flu-like symptoms that resolve with supportive care. Prophylactic tocilizumab, an IL-6 receptor blocker, has become a common strategy. Some centers use a standard dose, and emerging data suggest that a lower dose of tocilizumab (4 mg/kg instead of 8 mg/kg) may be similarly effective at preventing CRS during step-up dosing.¹⁰ Once patients are past the initial dosing phase, the risk of CRS drops sharply and rarely recurs with ongoing treatment.

Infections and Low Blood Counts

Because elranatamab activates the immune system in a focused way, it also disrupts normal immune function. Infections are a real concern. A pooled analysis of bispecific antibody therapies in myeloma identified several pathogens associated with elranatamab treatment, including Pseudomonas pneumonia, cytomegalovirus (CMV) reactivation, and COVID-19.¹¹ CMV reactivation appears to be tied to the profound lymphopenia (a severe drop in lymphocyte counts) that occurs during the first weeks of treatment. In one case series of five patients, all developed grade 3 or worse lymphopenia, and CMV reactivated in the setting of these depleted immune cells.¹²

Beyond lymphopenia, drops in neutrophils, hemoglobin, and platelets are common, especially during the first several treatment cycles. Exposure-safety analyses confirm that the majority of severe blood count drops happen early in treatment and tend to stabilize over time.¹³ Your treatment team will monitor blood counts closely, particularly in the first months, and may use antimicrobial prophylaxis, immunoglobulin supplementation, and vaccination strategies to shore up your defenses. Expert guidance now frames infection prevention in phases: a pretreatment screening period, an active-therapy period with the highest infection risk, and a long-term follow-up phase.¹⁴

Neurologic Side Effects

Immune effector cell-associated neurotoxicity syndrome (ICANS) is rarer than CRS but more worrying when it occurs. ICANS involves confusion, tremor, difficulty speaking, or in severe cases, seizures or loss of consciousness. It tends to show up within the first ten days of treatment. In a real-world single-center report covering 12 patients treated with elranatamab, one patient developed grade 2 ICANS, which resolved within three days after delaying the next dose and adding dexamethasone.¹⁵

One case report described a more severe event: a patient with a prior history of cerebral hemorrhage developed grade 4 ICANS alongside mild CRS. High-dose steroids were needed to manage it, and imaging did not show new brain abnormalities. The authors noted that a history of brain events could contribute to the risk of more severe ICANS, though this link is uncertain.¹⁶ Overall, the evidence so far suggests ICANS with elranatamab is uncommon and usually low-grade, but monitoring during the step-up phase is essential.

Patients Previously Treated with BCMA-Targeted Therapies

A natural question for patients and oncologists is whether elranatamab still works if you have already received a BCMA-directed treatment, such as a CAR-T therapy or an antibody-drug conjugate. A pooled analysis from the MagnetisMM studies showed an overall response rate of about 45% in patients with prior BCMA-directed therapy, lower than the 61% seen in BCMA-naive patients but still meaningful for a population with extremely limited options. Among those who had received prior CAR-T cells specifically, the response rate was roughly 53%. Duration of response remained encouraging, with about 72% of responders still in response at nine months.¹⁷

The safety profile in BCMA-exposed patients did not show new or worse side effects compared with BCMA-naive patients. Quality-of-life data also held up: over half of BCMA-exposed patients perceived their disease as improved by day 15 of the first cycle.⁵ This matters because sequencing of BCMA-targeted treatments is one of the most active debates in myeloma care right now, and the data support using elranatamab even after prior BCMA-directed therapy.

Moving Step-Up Dosing to an Outpatient Setting

Traditionally, the step-up doses of bispecific antibodies have been given in the hospital, with patients admitted for 24 to 48 hours of monitoring after each dose. This is resource-intensive and inconvenient. Several centers have now tested outpatient protocols, and the results are encouraging. In one program covering 52 patients, step-up dosing was administered in the outpatient clinic with premedication and prophylactic tocilizumab. CRS occurred in about 19% of patients, nearly all grade 1 or 2, and only four patients (about 8%) required hospitalization for toxicity management. All patients recovered without complications.¹⁸

Another program implementing outpatient elranatamab step-up dosing used dexamethasone alone for CRS prophylaxis (without tocilizumab) alongside close monitoring and clear instructions for patients to present to a care center if fever or neurologic changes developed. The investigators concluded that the approach reduced inpatient stays and eased healthcare resource burdens.¹⁹ Outpatient step-up is not for everyone. Patient selection matters: you need reliable access to an emergency facility, the ability to self-monitor temperature and symptoms at home, and a caregiver available during the first several days. But for patients who meet these criteria, avoiding hospitalization is a real quality-of-life win.

How Elranatamab Compares to Other Options

Elranatamab is not the only bispecific antibody or immunotherapy for relapsed myeloma. Teclistamab, talquetamab, linvoseltamab, and the CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) all target overlapping patient populations. No head-to-head trials exist between these treatments, so researchers rely on indirect comparisons adjusting for differences in trial populations. One such comparison found that elranatamab showed significantly better response rates, duration of response, progression-free survival, and overall survival than teclistamab.²⁰

A broader systematic review of indirect comparisons painted a more complex picture. While elranatamab looked favorable against teclistamab across multiple endpoints, linvoseltamab showed improvements over elranatamab in response rates and complete response rates. Meanwhile, cilta-cel appeared to outperform several bispecific antibodies on depth-of-response measures.²¹ These indirect comparisons have limitations and should be interpreted cautiously. In clinical practice, the choice between elranatamab and an alternative often comes down to practical factors: CAR-T therapies require a manufacturing slot and waiting period, bispecific antibodies can start immediately, and some patients may not qualify for cell therapy due to fitness or logistics.

Special Populations

Elranatamab has shown feasibility in some populations that are typically hard to treat. A case report documented a patient with severe kidney impairment requiring hemodialysis who achieved a very good partial remission within seven weeks of starting elranatamab. CRS occurred during the initial doses but was managed with tocilizumab and dexamethasone, and treatment continued without major complications.²² This is a single case, so it does not establish broad safety in dialysis patients, but it suggests the drug can be used when kidney failure limits other options.

Patients with high-risk cytogenetics, which are genetic changes in myeloma cells that predict a worse prognosis, showed response rates in MagnetisMM-3 that were consistent with the overall population.⁴ Emerging data also support efficacy in patients who have already been exposed to BCMA-targeted therapies, expanding the pool of patients who stand to benefit.²³

When Elranatamab Stops Working

Resistance to BCMA-targeted therapies can develop through several routes. The most straightforward is target loss: myeloma cells can lose the BCMA protein from their surface entirely, usually through deletions in the gene (TNFRSF17) that encodes it. In some patients, small subclones of myeloma cells that already lacked BCMA were present before treatment and simply expanded once the BCMA-positive cells were killed off. In other cases, mutations in BCMA’s outer domain changed the protein’s shape enough that the drug could no longer bind effectively, even though BCMA was still technically present on the cell surface.²⁴

These resistance mechanisms are considered relatively uncommon so far, but they are a focus of active research. Understanding them matters for treatment sequencing: if a patient relapses on elranatamab because of BCMA loss, switching to another BCMA-targeted therapy is unlikely to help. A treatment targeting a different antigen entirely, such as GPRC5D (the target of talquetamab), may be the more rational next move. Some clinical programs are already exploring combinations and sequences designed to hit myeloma through multiple antigens to delay or prevent escape.